ArticleACS bio & med chem Au2026
Fine-Tuning a Transformer Model for METTL3 Lead Optimization.
Article in ACS bio & med chem Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transformers are machine learning models originally developed to translate between natural languages. Recently, a transformer model was trained on knowledge of medicinal chemistry, i.e., matched molecular pairs of nearly a million bioactive compounds from the ChEMBL database. Here, we customize (i.e., fine-tune) the pretrained model to enhance the affinity and/or metabolic stability of a series of inhibitors of methyltransferase-like protein 3 (METTL3). We first fine-tune the transformer model using a data set of about 500 METTL3 inhibitors with known binding affinities and validate it by retrospective analysis. Then, we fine-tune the original transformer model to simultaneously optimize binding affinity and metabolic stability in a prospective application. Two of the five METTL3 inhibitors predicted by the multiobjective optimized model show low-nanomolar potency and higher stability than the lead compound of the chemical series used for fine-tuning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.